Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disease characterized by intravascular hemolysis due to the targeting of affected red blood cells by the complement system. Eculizumab and ravulizumab are two monoclonal antibodies that inhibit the complement system’s components and have been shown to significantly improve survival and quality of life. This review describes the role of these monoclonal antibodies in the treatment of PNH with an emphasis on their safety profile. The challenges in the use of these drugs and new drugs in various stages of drug development are also described, which may be helpful in addressing some of these challenges.
All Keywords
【저자키워드】 Ravulizumab, eculizumab, challenges, Adverse drug reaction, paroxysmal nocturnal hemoglobinuria, investigational new drugs,
【저자키워드】 Ravulizumab, eculizumab, challenges, Adverse drug reaction, paroxysmal nocturnal hemoglobinuria, investigational new drugs,